Sign in

You're signed outSign in or to get full access.

NP

Nuvectis Pharma, Inc. (NVCT)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered typical development-stage financials with no revenue, a net loss of $5.33M (–$0.27 EPS), and cash of $29.86M after a February equity raise; EPS modestly missed S&P Global consensus (–$0.27 vs –$0.254*) largely on higher R&D and a $0.5M one-time charge .
  • Operationally, NXP900 showed robust pharmacodynamic response and acceptable safety up to 250 mg/day with >90% SRC inhibition in samples at clinically relevant exposures, supporting imminent progression to Phase 1b (single-agent in biomarker-selected tumors and combinations in NSCLC) .
  • NXP800 Phase 1b enrollment in platinum-resistant, ARID1a-mutated ovarian cancer continued; management reiterated an update “in a couple of months,” keeping 2H-2025 efficacy readouts on the radar .
  • Financing extended cash runway “into 1Q2027,” reducing near-term financing overhang as the pipeline transitions to Phase 1b data catalysts .
  • Near-term stock catalysts: NXP800 Phase 1b update timing and initiation/initial patient experience for NXP900 Phase 1b (including combination strategies with EGFR/ALK inhibitors) .

What Went Well and What Went Wrong

  • What Went Well

    • NXP900 de-risked mechanism: strong PD effect with acceptable safety through 250 mg/day; >90% SRC inhibition at clinically relevant concentrations; no DLT identified up to 250 mg/day .
    • Clear clinical path: Phase 1b to enroll biomarker-selected patients (YES1 amplification/Hippo pathway alterations) and to explore EGFR/ALK inhibitor combinations to address resistance in NSCLC .
    • Balance sheet de-risked: February raise (net $14.0M) supports runway into 1Q2027, aligning capital with upcoming milestones .

  • What Went Wrong

    • Modest EPS miss vs S&P Global consensus (–$0.27 actual vs –$0.254*), driven by higher R&D and a $0.5M one-time non-recurring charge in the quarter .
    • YoY operating intensity increased: R&D $3.68M vs $2.66M YoY; G&A $1.89M vs $1.74M, lifting operating loss to $5.57M from $4.40M YoY .
    • Disclosure inconsistency: press release compares Q1’25 R&D ($3.7M) to “Q1’23” in one place (likely Q1’24), though the detailed financial table provides the proper Q1’24 comparison; investors should rely on the tabled data .

Financial Results

MetricQ3 2024Q4 2024Q1 2025Q1 2025 Consensusvs Est.
Revenue ($USD Millions)$0.00 (no product revenue) $0.00 (no product revenue) $0.00 (no product revenue) $0.00*In line
EPS (Diluted) ($)$(0.24) $(0.36) $(0.27) $(0.254)*Miss by $(0.016)
Net Loss ($USD Millions)$(4.15) N/A (not disclosed quarterly)$(5.33) ——
Operating Loss ($USD Millions)$(4.36) N/A$(5.57) ——
R&D Expense ($USD Millions)$2.82 N/A$3.68 ——
G&A Expense ($USD Millions)$1.54 N/A$1.89 ——
Finance/Interest Income ($USD Millions)$0.21 N/A$0.24 ——
Cash & Equivalents ($USD Millions, period-end)$17.17 $18.53 $29.86 ——

Notes: Asterisks (*) denote S&P Global estimates. Values retrieved from S&P Global. Revenue presented as $0.00 reflects absence of product revenue lines in the statements.

  • YoY comparisons (Q1 2025 vs Q1 2024): Net loss $5.33M vs $4.17M; R&D $3.68M vs $2.66M; G&A $1.89M vs $1.74M; Interest income $0.24M vs $0.23M .
  • One-time non-recurring charges in Q1 2025 totaled $0.5M .

No segments or gross/operating margins apply given no revenue base .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayMulti-year“Into 2027” (post-Feb 2025 offering) “Into 1Q2027” Maintained/clarified
NXP900 Phase 1b start2025“Begin mid-2025” “Commence shortly after Phase 1a conclusion; coming months” Maintained
NXP800 Phase 1b update2025“Update in Q2 2025” “Update in a couple of months” Maintained (timing reiterated)
Revenue/Margins/OpEx/Tax/Dividends2025No guidance provided No guidance provided Unchanged

Earnings Call Themes & Trends

TopicQ3 2024 (Prev-2)Q4 2024 (Prev-1)Q1 2025 (Current)Trend
NXP900 clinical profile4 escalation cohorts cleared; no DLTs; dose escalation continues Enrollment continues; Phase 1b prep underway Robust PD, acceptable safety to 250 mg/day; >90% SRC inhibition; Phase 1b imminent; combos with EGFR/ALK Improving evidence; de-risking
NXP800 programAnticipated Phase 1b update in platinum-resistant ARID1a ovarian Ca; ODD/FTD highlights 75 mg/day intermittent dosing; update in Q2 2025 Enrollment continues; update “in a couple of months” Stable execution; update pending
Combination strategy (NSCLC)Planning combinations to overcome resistance Phase 1b monotherapy + EGFR/ALK combos planned Preclinical data at AACR support combos with EGFR/ALK inhibitors to reverse resistance Strengthening scientific rationale
Capital runway“Well into 2026” Into 2027 after Feb raise Into 1Q2027 Improved then stable
Regulatory/designationsODD/FTD status underscored (NXP800) ODD restated; program momentum No new designations; focus on clinical progress No change

Management Commentary

  • “We are approaching the conclusion of [NXP900 Phase 1a]… and are completing our preparations for the Phase 1b portion… patients with cancers harboring specific genetic alterations will be enrolled to evaluate… the therapeutic potential of single agent NXP900” .
  • “Recent AACR preclinical poster presentations highlight the potential of NXP900 as a combination partner to market-leading EGFR and ALK kinase inhibitors… aimed at overcoming acquired resistance… in NSCLC” .
  • “Enrollment into the [NXP800] Phase 1b study… continues, and we expect to provide an update… in a couple of months” .
  • “Completed $15.5M financing, extending projected cash runway into 1Q2027” .

Q&A Highlights

  • A Q1 2025 earnings call transcript was not available in the company document corpus; management updates were communicated via the May 6 press release and related scientific announcements (AACR) .

Estimates Context

  • EPS: Actual –$0.27 vs S&P Global consensus –$0.254* → modest miss of –$0.016, driven by higher R&D and a $0.5M one-time charge in the quarter .
  • Revenue: Consensus $0.0*; actual no product revenue (development stage) .

Note: Asterisks (*) denote S&P Global estimates. Values retrieved from S&P Global.

KPIs (Program and Financial Operating Metrics)

KPIQ3 2024Q4 2024Q1 2025
NXP900 dose escalation status4 cohorts cleared; no DLTs Enrollment continues; Phase 1b prep DLT not identified up to 250 mg/day; robust PD; >90% SRC inhibition at clinically relevant exposure
NXP900 next stepsPlanning monotherapy + combination approaches Phase 1b expected mid-2025 Phase 1b “in coming months”; combos with EGFR/ALK planned
NXP800 Phase 1b statusUpdate expected in Nov 2024 75 mg/day intermittent dosing; update in Q2 2025 Enrollment continues; update “in a couple of months”
Cash & equivalents (period-end)$17.17M $18.53M $29.86M
Cash runway“Well into 2026” Into 2027 Into 1Q2027

Why the Quarter Looked This Way

  • R&D and G&A step-up: R&D rose to $3.68M (from $2.66M YoY) supporting advancement of both programs; G&A rose to $1.89M (from $1.74M YoY); these increases, plus a $0.5M one-time charge, widened operating and net loss, pressuring EPS modestly below consensus .
  • Capital actions: February financing (net $14.0M) and ATM usage drove cash to $29.9M, aligning liquidity with Phase 1b initiations and near-term readouts .
  • Clinical execution: NXP900 pharmacodynamic/PK/safety progress at AACR supports a higher-conviction Phase 1b design (biomarker-selected monotherapy and combination strategies in NSCLC) that could unlock efficacy signals and investor focus .

Key Takeaways for Investors

  • EPS miss was small (–$0.016) and attributable to pipeline investment and a one-time charge; thesis remains driven by clinical catalysts, not near-term P&L .
  • NXP900’s PD/safety profile de-risks entry into Phase 1b; combinations with EGFR/ALK could address resistance biology in NSCLC, a meaningful value-creation path if efficacy signals emerge .
  • NXP800 Phase 1b update timing remains near-term; clarity on response durability/tolerability at 75 mg/day intermittent dosing will be important for program momentum .
  • Cash runway into 1Q2027 lowers financing overhang risk across multiple data events, improving the setup for clinical readouts .
  • Watch for: Phase 1b initiation details (biomarkers, cohorts), combination trial starts, and first Phase 1b efficacy signals that could reshape perception of both programs’ addressable markets .
  • Risk checks: Early-stage binary risk remains high; ensure discipline around position sizing into readouts given lack of revenue and historical biotech volatility .

Citations

  • Q1 2025 8-K and Exhibit 99.1 (press release and financials):
  • Q1 2025 Press release (duplicate of Exhibit 99.1 with tables):
  • AACR NXP900 press release (April 29, 2025):
  • FY 2024 results (Feb 25, 2025) and context:
  • Q3 2024 results (Nov 5, 2024):

S&P Global estimates

  • EPS and Revenue consensus for Q1 2025 marked with asterisks (*) above. Values retrieved from S&P Global.